Forte Biosciences
Company Details
Status: Public
Employees: 11-50
Location:
Dallas, Texas, United States
Type:
sample
Technology:
sample
sample
sample
About: Forte Biosciences is a clinical-stage biopharmaceutical company whose lead product candidate is FB102. FB102 is a proprietary molecule with potentially broad autoimmune and autoimmune-related applications. The Company’s FB102 program aims to address key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. Significant reductions in NK cell pharmacodynamic marker of FB102 mechanism was observed supporting the in vitro as well as the NHP data and mechanism of action of FB102. A phase 1 healthy volunteer SAD/MAD study was successfully completed and demonstrated a good safety profile. We initiated patient-based studies in celiac disease in the third quarter of 2024.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Forte Biosciences | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.